Evidence map›Paper›PMID 40910948›Full record

ArticleInternational immunology2026

Anti-human TLR7 antibody for therapeutic intervention in systemic lupus erythematosus.

Ryutaro Fukui, Yusuke Murakami, Atsuo Kanno, Yuji Motoi, Atsushi Manno, Tomohiro Honda, Shinnosuke Yamada, Jun Ishiguro, Takashi Kagari, Kensuke Nakamura and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ryutaro FukuiDivision of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yusuke MurakamiDivision of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Atsuo KannoDivision of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yuji MotoiDivision of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Atsushi MannoDiscovery Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Tomohiro HondaTranslational Science Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Shinnosuke YamadaTranslational Science Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Jun IshiguroDiscovery Research Laboratories V, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Takashi KagariDiscovery Research Laboratories I, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Kensuke NakamuraModality Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Michinori KadokuraModality Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Takashi IsobeTranslational Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Yoshiaki TomimoriTranslational Science, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.
Jun TanakaTranslational Science Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Giorgio SenaldiClinical Development, Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.
Toshiyuki ShimizuGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-0547-8922
Kensuke MiyakeDivision of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Funding

Daiichi Sankyo Co., LtdJapan Society for the Promotion of Science 16H06388Japan Society for the Promotion of Science 21H04800Japan Society for the Promotion of Science 22H05184Japan Society for the Promotion of Science 22K19424Japan Society for the Promotion of Science 24K22045Japan Society for the Promotion of Science JP 16H06276Japan Society for the Promotion of Science JP19pc0101039Japan Society for the Promotion of Science JP22H05182Joint Research Project of The Institute of Medical ScienceJST Core Research for Evolutional Science and Technology JPMJCR21E4
6 · The paper itself

Abstract

Toll-like receptor 7 (TLR7) is an endosomal sensor that responds to both pathogen-derived and self-derived single-stranded RNA (ssRNA). Responses of TLR7 to self-derived ssRNA have been implicated in the development of autoimmune diseases, such as systemic lupus erythematosus (SLE). TLR7 antagonists and inhibitory anti-TLR7 monoclonal antibodies (mAbs) can protect lupus-prone NZBWF1 mice from lethal nephritis. However, less is known about TLR7 dependence and activation in human SLE, as both TLR7 and TLR8 respond to ssRNA in humans. Here, we analyzed public databases and found that TLR7 gene signature scores were consistently elevated across datasets, races, and SLEDAI scores compared to TLR8, suggesting a deeper involvement of TLR7 in SLE pathogenesis. To specifically inhibit human TLR7 responses, we developed inhibitory mAbs against human TLR7. Utilizing an inhibitory clone, we generated the humanized mAb, DS-7011a. DS-7011a effectively inhibited TLR7-mediated responses in plasmacytoid dendritic cells (pDCs) and B cells. Furthermore, DS-7011a was internalized in a TLR7-dependent manner and accumulated in B cells, pDCs, conventional dendritic cells (cDCs), and monocytes/macrophages. In this study, we describe the generation and preclinical development of DS-7011a, which has the potential to be a therapeutic option for the treatment of SLE.

Indexed as

Antibodies, MonoclonalLupus Erythematosus, SystemicToll-Like Receptor 7AnimalsB-LymphocytesDendritic CellsFemaleHumansMiceAntibodies, MonoclonalTLR7 protein, humanToll-Like Receptor 7antibody drugautoimmunitygene signaturehumanized antibody

Identifiers

PMID40910948
PMCPMC12802918

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.